- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02498340
Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation
July 14, 2015 updated by: Mohsen Saleh Elalfy, Ain Shams University
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is prevalent and add a burden on families in Egypt and Middle East due to lifelong diet restriction, non-fava beans diet is main food for most families in the region and parents and doctors consider it as a prohibited food whatever the genetic or clinical phenotypes.
The effective management is avoiding a spectrum of food and drugs causing oxidative stress.
No data is available about the hazards of consumption of non-fava beans diet.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Investigate the effect of challenge of non-fava beans diet on occurrence of hemolysis in both common and rare mutations causing G6PD deficiency in Egyptian children as well as making a genotype-phenotype correlation.
Patients and Methods: The study will include all G6PD deficient children who were regularly followed up in Pediatric Hematology Center, Ain Shams University over last decade from 2004-2014 who stopped eating non fava-bean diet since their diagnosis as G6PD deficient and willing to participate in the diet challenge.
They will be enrolled in a one year prospective study involving quantitative analyses for enzymatic activity, and molecular typing of G6PD enzyme using a polymerase chain reaction-amplification refractory mutation system (PCR-ARMS) technique.
Patient's medical records will be reviewed as history of blood transfusion and G6PD level at diagnosis.
Initial phase will be dietetic challenge with ingestion of non-fava beans taken in small amount (10-20 gm/day for 3 successive days ) for children with haemoglobin level ≥ 11 gm/dl with daily clinical and laboratory monitoring by complete blood count, and markers of hemolysis as well as measurement of malondialdehyde (MDA) level both basal and at study end.
A drop of Hb of ≥0.5 gm/dl and / or appearance of hemoglobinuria is considered a significant hemolysis.
Patients who will not meet the definition of significant hemolysis will be prospectively followed up for one year with follow up during their chronic exposure by complete blood count and hemolysis markers/ 3 months.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Pediatric Hematology clinic, Ain Shams University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All children with proved enzymatic deficiency of G6PD.
- Patients who met the criteria of hemoglobin level at study time ≥ 11 gm/dl
Exclusion Criteria:
- patients with another enzyme deficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Diet challenge
The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
|
Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Diet challenge
Time Frame: one year
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Anticipated)
July 1, 2016
Study Registration Dates
First Submitted
July 10, 2015
First Submitted That Met QC Criteria
July 14, 2015
First Posted (Estimate)
July 15, 2015
Study Record Updates
Last Update Posted (Estimate)
July 15, 2015
Last Update Submitted That Met QC Criteria
July 14, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Diet challenge in G6PD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose-6-Phosphate Dehydrogenase Deficiency
-
University of Mississippi, OxfordCompletedMalaria | Glucose 6 Phosphate Dehydrogenase DeficiencyUnited States
-
PATHUniversity of Oxford; Mahidol UniversityCompletedGlucose-6 Phosphate Dehydrogenase DeficiencyThailand
-
PATHEijkman Institute for Molecular BiologyCompletedGlucose-6-Phosphate Dehydrogenase DeficiencyIndonesia
-
Centre Hospitalier de Saint-DenisCompletedSickle Cell Disease | Acute Chest Syndrome | Anti-Bacterial Agents | Glucose-6-Phosphate Dehydrogenase Deficiency | MacrolidesFrance
-
University of UtahNot yet recruitingPyruvate Kinase Deficiency | Glucose 6 Phosphate Dehydrogenase DeficiencyUnited States
-
Southern Medical University, ChinaUnknownNeonatal HyperbilirubinemiaChina
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruitingStroke | G6PD DeficiencyChina
-
F.I.R.M.O. - Fondazione Italiana Ricerca sulle...Not yet recruitingPhosphate Overload | Phosphate DeficiencyItaly
-
Oregon Health and Science UniversityCompletedNormal Volunteers | Trifunctional Protein Deficiency | Very Long-chain Acyl-CoA Dehydrogenase Deficiency | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency | Medium-chain Acyl-CoA Dehydrogenase Deficiency | Carnitine Palmitoyltransferase II Deficiency, MyopathicUnited States
-
West Kazakhstan Medical UniversityRecruitingOrnithine Transcarbamylase Deficiency | Biotinidase Deficiency | Citrullinemia | Glutaric Acidemia Type II | Argininosuccinic Aciduria | Maple Syrup Urine Disease | Primary Carnitine Deficiency | Homocystinuria | Carnitine Palmitoyltransferase II Deficiency | Arginase Deficiency | Very Long-chain Acyl-CoA... and other conditionsKazakhstan
Clinical Trials on non- fava beans
-
Vanderbilt UniversityCompletedHealthy ParticipantsUnited States
-
Cornell UniversityInstituto Nacional de Salud Publica, MexicoCompleted
-
Dr. Peter ZahradkaManitoba Pulse GrowersCompleted
-
University of Nebraska LincolnActive, not recruitingDietary Intervention | Gut MicrobiotaUnited States
-
University of Colorado, Colorado SpringsIowa State UniversityCompletedType 2 Diabetes
-
Arizona State UniversityUnited States Dry Bean CouncilCompletedType 2 Diabetes Mellitus | Blood GlucoseUnited States
-
University of AberdeenCompleted
-
University of AlbertaUniversity of Manitoba; Alberta Innovates Health Solutions; Pulse CanadaCompleted
-
University of TorontoOntario Ministry of Agriculture, Food and Rural AffairsCompletedHypertension | Obesity | Diabetes | Overweight | Metabolic SyndromeCanada